Disc Medicine IRON
NASDAQ IRON
$79.23 -0.14 (-0.18%)
As of: Sep 4, 2026 · 3:59 PM EDT

Disc Medicine (IRON) Gains from Investment Securities (2020)

Disc Medicine (IRON) posted quarterly Gains from Investment Securities of $2000.0 for Q4 2020, down 75.0% quarter-over-quarter from $8000.0 in Q3 2020.

Analysis

Disc Medicine (IRON) Gains from Investment Securities (2020) Analysis & Trends

Disc Medicine (IRON) has reported Gains from Investment Securities for 1 consecutive years, with $2000.0 the latest figure, recorded in Q4 2020.

  • In Q4 2020, Gains from Investment Securities changed N/A year-over-year to $2000.0; the TTM figure through Dec 2020 stood at $8000.0 (changed N/A YoY), while the FY2020 annual figure was $8000.0, changed N/A from the prior year.
  • Gains from Investment Securities fell to $2000.0 in Q4 2020 per IRON's latest filing, from $8000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $8000.0 in Q3 2020 and bottomed at -$2000.0 in Q1 2020.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Disc Medicine 3.06 Bn 3.06 Bn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2020 2,000.00
Sep 30, 2020 8,000.00
Mar 31, 2020 -2,000.00